Overview

Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis

Status:
Unknown status

Trial end date:
2019-12-14

Target enrollment:

Participant gender:

Summary

Azathioprine is considered first line immunomodulatory therapy for patients with ulcerative colitis. Up to 50% are treatment failures or experience adverse events leading to treatment withdrawal. Recent evidence suggests that the combination of allopurinol and low dose azathioprine increases the proportion of treatment responders and reduce the risk of adverse events. Objectives: To evaluate the beneficial and harmful effects of low dose azathioprine and allopurinol versus standard azathioprine monotherapy in patients with ulcerative colitis.

Phase:

Phase 3

Details

Lead Sponsor:

Hvidovre University Hospital

Collaborators:

Aalborg Universitetshospital
Aalborg University Hospital
Aarhus University Hospital
Bispebjerg Hospital
Odense University Hospital
Regional Hospital Viborg
Sydvestjysk Hospital Esbjerg
University Hospital Koge
University of Copenhagen
Vejle Hospital
Zealand University Hospital

Treatments:

Allopurinol
Azathioprine